Audentes Therapeutics, Inc. is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT). The Company's subsidiary is Audentes Therapeutics UK Ltd. As of September 30, 2016, the Company had not generated any revenues.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:BOLD
- CUSIP: N/A
- Web: www.audentestx.com
Capitalization:- Market Cap: $514 million
- Outstanding Shares: 21,889,000
Average Prices:- 50 Day Moving Avg: $19.75
- 200 Day Moving Avg: $16.88
- 52 Week Range: $13.06 - $22.82
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -4.86
- P/E Growth: -1.03
Sales & Book Value:- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: $5.83 per share
- Price / Book: 3.17
Profitability:- EBIDTA: ($73,430,000.00)
- Return on Assets: -49.68%
Debt:- Current Ratio: 10.06%
- Quick Ratio: 10.06%
Misc:- Average Volume: 137,653 shs.
- Short Ratio: 3.6
Frequently Asked Questions for Audentes Therapeutics (NASDAQ:BOLD)
What is Audentes Therapeutics' stock symbol?
Audentes Therapeutics trades on the NASDAQ under the ticker symbol "BOLD."
How were Audentes Therapeutics' earnings last quarter?
Audentes Therapeutics, Inc. (NASDAQ:BOLD) issued its quarterly earnings results on Thursday, August, 10th. The company reported ($0.87) EPS for the quarter, missing the consensus estimate of ($0.77) by $0.10. View Audentes Therapeutics' Earnings History.
Where is Audentes Therapeutics' stock going? Where will Audentes Therapeutics' stock price be in 2017?
3 brokerages have issued 12 month target prices for Audentes Therapeutics' shares. Their forecasts range from $20.00 to $24.00. On average, they expect Audentes Therapeutics' stock price to reach $22.25 in the next year. View Analyst Ratings for Audentes Therapeutics.
Who are some of Audentes Therapeutics' key competitors?
Some companies that are related to Audentes Therapeutics include Neuroderm Ltd (NDRM), Omeros Corporation (OMER), Acorda Therapeutics (ACOR), Dermira (DERM), Xencor (XNCR), Retrophin (RTRX), Ascendis Pharma A/S (ASND), Dynavax Technologies Corporation (DVAX), Sangamo Therapeutics (SGMO), Aduro Biotech (ADRO), Epizyme (EPZM), Amarin Corporation PLC (AMRN), Keryx Biopharmaceuticals (KERX), Five Prime Therapeutics (FPRX), Achaogen (AKAO), Insmed (INSM), PTC Therapeutics (PTCT) and ZIOPHARM Oncology (ZIOP).
Who are Audentes Therapeutics' key executives?
Audentes Therapeutics' management team includes the folowing people:
- Matthew R. Patterson, President, Chief Executive Officer, Co-Founder, Director
- Thomas J. Schuetz M.D. Ph.D., Co-Founder, Independent Director
- Thomas P. Soloway, Chief Financial Officer, Senior Vice President
- Natalie C. Holles, Chief Operating Officer, Senior Vice President
- David Nagler, Senior Vice President - Human Resources and Corporate Affairs
- John Gray Ph.D., Senior Vice President - Research and Development
- Mary Newman, Senior Vice President - Regulatory Affairs
- Suyash Prasad, Senior Vice President, Chief Medical Officer
- Jennifer Jarrett, Director
- Louis G. Lange M.D. Ph.D., Independent Director
When did Audentes Therapeutics IPO?
(BOLD) raised $75 million in an IPO on Wednesday, July 20th 2016. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.
Who owns Audentes Therapeutics stock?
Audentes Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include Versant Venture Management LLC (6.52%), Redmile Group LLC (6.67%), Jennison Associates LLC (3.05%), Vanguard Group Inc. (2.45%), Alliancebernstein L.P. (2.31%) and Franklin Resources Inc. (1.32%). Company insiders that own Audentes Therapeutics stock include 5Am Partners Iii, Llc, James E Flynn, Louis G Lange, Matthew R Patterson, Orbimed Advisors Llc and Versant Ventures Iv, Llc. View Institutional Ownership Trends for Audentes Therapeutics.
Who sold Audentes Therapeutics stock? Who is selling Audentes Therapeutics stock?
Audentes Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., FMR LLC, Goldman Sachs Group Inc., Victory Capital Management Inc. and Citadel Advisors LLC. Company insiders that have sold Audentes Therapeutics stock in the last year include Louis G Lange and Matthew R Patterson. View Insider Buying and Selling for Audentes Therapeutics.
Who bought Audentes Therapeutics stock? Who is buying Audentes Therapeutics stock?
Audentes Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Redmile Group LLC, Jennison Associates LLC, Vanguard Group Inc., State Street Corp, Alliancebernstein L.P., Sphera Funds Management LTD., Northern Trust Corp and TIAA CREF Investment Management LLC. Company insiders that have bought Audentes Therapeutics stock in the last two years include 5Am Partners Iii, Llc, James E Flynn, Orbimed Advisors Llc and Versant Ventures Iv, Llc. View Insider Buying and Selling for Audentes Therapeutics.
How do I buy Audentes Therapeutics stock?
Shares of Audentes Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Audentes Therapeutics' stock price today?
One share of Audentes Therapeutics stock can currently be purchased for approximately $18.50.
MarketBeat Community Rating for Audentes Therapeutics (NASDAQ BOLD)MarketBeat's community ratings are surveys of what our community members think about Audentes Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Earnings History for Audentes Therapeutics (NASDAQ:BOLD)Earnings History by Quarter for Audentes Therapeutics (NASDAQ BOLD)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 8/10/2017 | Q2 2017 | ($0.77) | ($0.87) | | | View | N/A |  |
| 5/11/2017 | Q1 2017 | ($0.92) | ($0.83) | | | View | N/A | |
| 3/9/2017 | 12/31/2016 | ($0.75) | ($0.91) | | | View | N/A | |
| 11/10/2016 | Q3 2016 | ($0.66) | ($0.94) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Audentes Therapeutics (NASDAQ:BOLD)2017 EPS Consensus Estimate: ($3.32)
2018 EPS Consensus Estimate: ($3.22)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | ($0.93) | ($0.93) | ($0.93) |
| Q2 2017 | 2 | ($0.84) | ($0.69) | ($0.77) |
| Q3 2017 | 2 | ($0.86) | ($0.80) | ($0.83) |
| Q4 2017 | 2 | ($0.87) | ($0.72) | ($0.80) |
| Q1 2018 | 1 | ($0.78) | ($0.78) | ($0.78) |
| Q2 2018 | 1 | ($0.80) | ($0.80) | ($0.80) |
| Q3 2018 | 1 | ($0.81) | ($0.81) | ($0.81) |
| Q4 2018 | 1 | ($0.83) | ($0.83) | ($0.83) |
(Data provided by Zacks Investment Research)
Dividend History for Audentes Therapeutics (NASDAQ:BOLD)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Audentes Therapeutics (NASDAQ:BOLD)Insider Ownership Percentage: 47.30%
Institutional Ownership Percentage: 59.76%
Insider Trades by Quarter for Audentes Therapeutics (NASDAQ:BOLD)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 7/13/2017 | Matthew R Patterson | CEO | Sell | 15,000 | $20.00 | $300,000.00 | |
| 7/12/2017 | Matthew R Patterson | CEO | Sell | 2,850 | $20.00 | $57,000.00 | |
| 6/26/2017 | Louis G Lange | Director | Sell | 15,000 | $19.78 | $296,700.00 | |
| 4/24/2017 | 5Am Partners Iii, Llc | Insider | Buy | 172,413 | $14.50 | $2,499,988.50 | |
| 7/25/2016 | James E Flynn | Insider | Buy | 400,000 | $15.00 | $6,000,000.00 | |
| 7/25/2016 | Orbimed Advisors Llc | Director | Buy | 33,334 | $15.00 | $500,010.00 | |
| 7/25/2016 | Versant Ventures Iv, Llc | Major Shareholder | Buy | 35,000 | $15.00 | $525,000.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Audentes Therapeutics (NASDAQ:BOLD)
Latest Headlines for Audentes Therapeutics (NASDAQ:BOLD)
| Source: |
|
| Date | Headline |
|---|
 | Audentes Therapeutics, Inc. (BOLD) Now Covered by Evercore ISI
www.americanbankingnews.com - August 16 at 6:26 PM |
| Audentes Therapeutics, Inc. (BOLD) Downgraded to "Sell" at Zacks Investment Research
www.americanbankingnews.com - August 14 at 6:38 PM |
| Leerink Swann Comments on Audentes Therapeutics, Inc.'s Q3 2017 Earnings (NASDAQ:BOLD)
www.americanbankingnews.com - August 14 at 3:36 AM |
| Audentes Therapeutics Inc (BOLD) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - August 14 at 2:44 AM |
| Audentes Therapeutics, Inc. (BOLD) Posts Earnings Results, Misses Estimates By $0.10 EPS
www.americanbankingnews.com - August 11 at 6:02 PM |
 | Audentes Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - August 10 at 5:49 PM |
| Audentes Therapeutics reports 2Q loss
finance.yahoo.com - August 10 at 5:49 PM |
| Audentes Therapeutics, Inc. (BOLD) Downgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - August 8 at 5:44 PM |
| Audentes Therapeutics, Inc. (BOLD) Expected to Announce Earnings of -$0.79 Per Share
www.americanbankingnews.com - July 31 at 9:06 AM |
| Audentes Therapeutics Inc (BOLD) Upgraded by ValuEngine to Hold
www.americanbankingnews.com - July 21 at 12:44 AM |
| Audentes Therapeutics Inc (NASDAQ:BOLD) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - July 21 at 12:28 AM |
| Audentes Therapeutics Announces Appointment of Fulvio Mavilio, Ph.D. to Vice President Scientific Affairs, Europe
finance.yahoo.com - July 18 at 6:06 PM |
| Audentes Therapeutics, Inc. (BOLD) Upgraded to Buy at Zacks Investment Research
www.americanbankingnews.com - July 17 at 5:20 PM |
| Audentes Therapeutics, Inc. (BOLD) CEO Sells $57,000.00 in Stock
www.americanbankingnews.com - July 14 at 10:56 PM |
| Insider Selling: Audentes Therapeutics, Inc. (BOLD) CEO Sells 15,000 Shares of Stock
www.americanbankingnews.com - July 14 at 10:56 PM |
| -$0.79 Earnings Per Share Expected for Audentes Therapeutics, Inc. (BOLD) This Quarter
www.americanbankingnews.com - July 6 at 10:16 PM |
| Audentes Therapeutics, Inc. (BOLD) Director Louis G. Lange Sells 15,000 Shares
www.americanbankingnews.com - June 28 at 7:40 PM |
| Audentes Therapeutics Announces Participation in Upcoming Investor Conferences
finance.yahoo.com - June 28 at 4:42 PM |
| Brokerages Expect Audentes Therapeutics, Inc. (BOLD) to Post ($0.79) Earnings Per Share
www.americanbankingnews.com - June 21 at 6:15 PM |
| Audentes Therapeutics Appoints Jennifer Jarrett to Board of Directors
finance.yahoo.com - June 13 at 1:00 PM |
| Zacks: Analysts Anticipate Audentes Therapeutics, Inc. (BOLD) Will Announce Earnings of -$0.79 Per Share
www.americanbankingnews.com - June 12 at 10:22 PM |
| Brokerages Expect Audentes Therapeutics Inc (BOLD) to Post ($0.76) EPS
www.americanbankingnews.com - June 2 at 12:30 AM |
| Audentes Therapeutics Inc (BOLD) Short Interest Update
www.americanbankingnews.com - May 28 at 8:20 PM |
| Why Audentes Therapeutics (BOLD) Could Be Positioned for a Surge
finance.yahoo.com - May 19 at 3:56 PM |
| Q2 2017 EPS Estimates for Audentes Therapeutics Inc Lifted by Analyst (BOLD)
www.americanbankingnews.com - May 17 at 8:08 AM |
| Audentes Therapeutics Inc (BOLD) Expected to Post Earnings of -$0.82 Per Share
www.americanbankingnews.com - May 16 at 8:24 AM |
| Audentes Therapeutics Inc (BOLD) Receives Ourperform Rating from Wedbush
www.americanbankingnews.com - May 15 at 9:34 PM |
 | BRIEF-Audentes Therapeutics qtrly loss per share $0.83
www.reuters.com - May 13 at 2:36 AM |
| Audentes Therapeutics Inc (BOLD) Issues Quarterly Earnings Results
www.americanbankingnews.com - May 12 at 12:56 PM |
| Audentes Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - May 11 at 9:14 AM |
| Audentes Therapeutics reports 1Q loss
finance.yahoo.com - May 11 at 9:14 AM |
| Audentes Therapeutics Inc (BOLD) Upgraded at Zacks Investment Research
www.americanbankingnews.com - May 10 at 5:22 PM |
| Audentes Therapeutics Inc (BOLD) Given Consensus Rating of "Strong Buy" by Brokerages
www.americanbankingnews.com - May 9 at 6:38 PM |
 | Audentes Therapeutics (BOLD) Names John T. Gray, Ph.D. as SVP and Chief Scientific Officer
www.streetinsider.com - May 8 at 8:54 PM |
| Audentes Therapeutics Announces Appointment of John T. Gray, Ph.D. to Senior Vice President and Chief Scientific Officer
finance.yahoo.com - May 8 at 10:26 AM |
| Audentes Therapeutics Inc (BOLD) Expected to Post Q1 2017 Earnings of ($0.93) Per Share
www.americanbankingnews.com - May 4 at 8:04 AM |
| Audentes Therapeutics (BOLD) Announces Presentation of Data at ASGCT
www.streetinsider.com - May 4 at 2:04 AM |
| Audentes Therapeutics Announces Presentation of Data at the American Society of Gene and Cell Therapy Annual Meeting
finance.yahoo.com - May 3 at 9:26 AM |
| Audentes Therapeutics Inc (BOLD) Coverage Initiated by Analysts at Leerink Swann
www.americanbankingnews.com - May 2 at 12:04 AM |
| Insider Buying: Audentes Therapeutics Inc (BOLD) Insider Buys 172,413 Shares of Stock
www.americanbankingnews.com - April 26 at 10:52 PM |
| -$0.92 EPS Expected for Audentes Therapeutics Inc (BOLD) This Quarter
www.americanbankingnews.com - April 25 at 5:18 PM |
| Audentes Therapeutics Inc (BOLD) Given Average Rating of "Strong Buy" by Analysts
www.americanbankingnews.com - April 24 at 4:42 PM |
| Audentes Therapeutics (BOLD) Prices 5.2M Share Offering at $14.50/Sh
www.streetinsider.com - April 19 at 1:12 PM |
| Audentes Therapeutics Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - April 19 at 1:12 PM |
| Audentes Therapeutics Gears Up for Secondary Offering
finance.yahoo.com - April 19 at 1:12 PM |
| Audentes Therapeutics Inc (BOLD) Lowered to "Sell" at Zacks Investment Research
www.americanbankingnews.com - April 17 at 5:57 PM |
| Audentes Therapeutics to Present at the ARM 5th Annual Cell & Gene Therapy Investor Day
finance.yahoo.com - April 17 at 12:26 PM |
| Zacks Investment Research Downgrades Audentes Therapeutics Inc (BOLD) to Sell
www.americanbankingnews.com - April 11 at 4:34 PM |
| Audentes Therapeutics Inc (BOLD) Cut to "Sell" at Zacks Investment Research
www.americanbankingnews.com - April 4 at 6:37 PM |
 | Audentes Therapeutics Announces FDA Clearance of Investigational New Drug Application for AT132 to Treat X-Linked Myotubular Myopathy
us.rd.yahoo.com - April 3 at 4:24 PM |
Audentes Therapeutics (BOLD) Chart for Friday, August, 18, 2017
